Miriam Kim, MD

Assistant Professor, Medicine

Our goal is to develop more effective immunotherapies for acute myeloid leukemia (AML). We work at the interface of hematopoietic stem and progenitor cells (HSPCs) and T cells, as AML is a malignancy derived from HSPCs and still harbors many characteristics of its normal counterparts. We use chimeric antigen receptor (CAR) T cell therapy, in which T cells are genetically engineered to attack cancer, as this has achieved success in a variety of hematologic malignancies, such as B-cell lymphoma, multiple myeloma, and acute lymphoblastic leukemia. We aim to extrapolate the success of CAR T cell therapy to AML.

Research keywords: CAR T cells; Hematopoietic stem cells; Cell and gene therapy

Basic information

Mentoring statement:Not provided.
Some former postdocs’ career outcomes:Not provided.

Postdoc openings within the next year

Number of postdoc positions:1
Postdoc eligibility:U.S. Citizens or Permanent Residents
Current Visa-Holding Trainees in the U.S.
International Trainees Outside the U.S.